Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. J of Skin. 2023;7(2):s175. doi:10.25251/skin.7.supp.175